Daily Sepsis Research Analysis
Analyzed 24 papers and selected 3 impactful papers.
Summary
Analyzed 24 papers and selected 3 impactful articles.
Selected Articles
1. Selenium nanoparticles as adjunctive therapy in sepsis: A pilot randomized clinical trial.
In a registered pilot RCT (n=70; 68 completed), adjunctive selenium nanoparticles (400 μg/day) improved immune function in septic patients, evidenced by higher total lymphocyte counts and increased absolute CD3+ T-cell counts versus standard care. The study supports feasibility and immunologic efficacy, warranting larger trials with clinical endpoints.
Impact: This first-in-patient randomized trial of SeNPs addresses sepsis-induced immunosuppression with a novel nanotechnology-based adjunct, demonstrating biologic activity on immune restoration.
Clinical Implications: If validated, SeNPs could serve as an adjunct to restore immunocompetence in sepsis with immune paralysis, potentially improving infection control and readiness for de-escalation. Current evidence supports pilot use only in trials.
Key Findings
- Registered pilot RCT in sepsis (ChiCTR2300072222) randomized 70 patients; 68 completed (34 per arm).
- Adjunctive SeNPs (400 μg/day) improved immune function with higher total lymphocyte counts.
- Increased absolute counts of CD3-positive T cells were observed in the SeNPs group versus control.
Methodological Strengths
- Randomized, registered clinical trial design with prespecified immunologic endpoints and serial measurements (days 1, 4, 7, 10).
- Active comparator (standard care) with equal allocation (1:1) enabling balanced groups.
Limitations
- Pilot sample size with short follow-up and surrogate immunologic endpoints rather than clinical outcomes.
- Blinding and adverse event reporting are not detailed in the abstract.
Future Directions: Conduct multicenter, adequately powered RCTs assessing mortality, secondary infections, and organ dysfunction; define optimal dosing, safety, and responder phenotypes (e.g., lymphopenic/endotype-defined patients).
Immunosuppression in sepsis often leads to treatment failure due to impaired host defense, underscoring an urgent need for novel therapeutic strategies to restore immune function. To address this challenge, we designed functional selenium nanoparticles (SeNPs) and conducted a pilot randomized clinical trial to evaluate the efficacy and safety of SeNPs in sepsis patients with immune dysfunction. The trial was registered with the Chinese Clinical Trial Registry (ChiCTR2300072222). Eligible patients were randomly assigned in 1:1 ratio to receive either standard care alone or standard care supplemented with SeNPs (400 μg selenium daily). The primary endpoint was immune function, assessed by lymphocyte counts and subsets on days 1, 4, 7, and 10 after randomization. Seventy patients were enrolled, and 68 completed the trial (34 per group). Compared with the control group, SeNPs supplementation was associated with improved immune function, reflected by higher total lymphocyte counts and increased absolute counts of CD3
2. The Endogenous Metabolite TDCA Ameliorates LPS-Driven Liver Injury via Modulation of Caspase-11/GSDMD-Mediated Pyroptosis.
In endotoxemia, hepatic TDCA levels rise and exogenous TDCA attenuates macrophage pyroptosis by suppressing caspase-11/GSDMD activation. In a lethal D-GalN/LPS liver injury model, TDCA (3 or 6 mg/kg) markedly improved survival, reduced liver enzymes and systemic IL-1β/IL-18, and mitigated histologic damage.
Impact: This study uncovers an endogenous bile acid–mediated mechanism that limits pyroptosis via caspase-11/GSDMD, linking metabolic adaptation to innate immune effector control with robust in vitro and in vivo validation.
Clinical Implications: Targeting caspase-11/GSDMD-mediated pyroptosis with bile acid–based modulators like TDCA may offer a therapeutic avenue for sepsis-associated liver injury; translation requires validation in clinically relevant sepsis models and safety profiling.
Key Findings
- LPS challenge elevated hepatic TDCA, indicating bile acid metabolic reprogramming in endotoxemia.
- TDCA dose-dependently reduced pyroptosis in macrophages (lower LDH, IL-1β/IL-18, and Oxazole yellow uptake).
- TDCA suppressed non-canonical inflammasome signaling (decreased caspase-11, GSDMD, and IL-1β activation).
- In D-GalN/LPS model, TDCA (3, 6 mg/kg) improved survival (40% and 80%), reduced ALT/AST and IL-1β/IL-18, and ameliorated histopathology.
Methodological Strengths
- Convergent in vitro and in vivo evidence with dose–response testing.
- Mechanistic readouts of pyroptosis and inflammasome activation (caspase-11, GSDMD, cytokines, LDH, dye uptake).
Limitations
- Toxin-sensitized D-GalN/LPS model may not capture polymicrobial or clinical sepsis complexity.
- Pathway necessity (e.g., genetic ablation of caspase-11 or GSDMD) was not demonstrated in this study.
Future Directions: Validate in clinically relevant sepsis models (e.g., CLP), define target engagement and necessity using genetic or pharmacologic inhibition of caspase-11/GSDMD, and assess safety/PK for translational development.
The liver is a central immunometabolic organ during endotoxemia and a major target of sepsis-related injury. Intriguingly, the liver exhibits a notable resilience to endotoxemia or septic insults, suggesting the activation of endogenous protective mechanisms. The bile acid taurodeoxycholic acid (TDCA) demonstrates hepatoprotective properties; nonetheless, its role and mechanism in lipopolysaccharide (LPS)-driven inflammatory liver injury remain elusive. This study reveals that LPS challenge induces significant reprogramming of hepatic bile acid metabolism, with TDCA being markedly elevated in LPS-challenged mice. In vitro, TDCA dose-dependently attenuated pyroptosis in bone marrow-derived macrophages, as evidenced by reduced lactate dehydrogenase (LDH) release, decreased interleukin-1 beta (IL-1β) and interleukin-18 (IL-18) secretion, and suppressed dye Oxazole yellow uptake. Consistent with reduced non-canonical inflammasome signaling, TDCA treatment was associated with decreased activation of caspase-11 and its downstream targets Gasdermin D (GSDMD) and IL-1β. In a lethal D-Galactosamine (D-GalN)/LPS-induced toxin-sensitized inflammatory liver injury model, therapeutic administration of TDCA (3, 6 mg/kg) profoundly improved survival rates (40% and 80%, respectively), attenuated liver injury, reduced alanine aminotransferase (ALT) and aspartate aminotransferase (AST), suppressed systemic inflammation (IL-1β and IL-18), and ameliorated histopathological damage. Crucially, TDCA treatment reduced the activation of the caspase-11/GSDMD pathway in the septic liver. Our findings demonstrate that TDCA is an endogenously mobilized bile acid that confers protection against LPS-driven inflammatory liver injury, with effects supporting a role for modulation of the Caspase-11/GSDMD pyroptotic pathway. These observations provide hypothesis-generating implications for sepsis-associated liver injury that warrant further validation in clinically relevant sepsis models and pathway-necessity studies.
3. A Novel Immune-Modulating Nanodrug Enhances Liver-Targeted mRNA Delivery.
An immune-modulating telodendrimer nanodrug suppressed endogenous and LPS-induced inflammation in liver cells and significantly enhanced mRNA/LNP delivery efficiency in liver cell systems, including primary human hepatocytes. The approach addresses inflammation-imposed barriers to liver-targeted mRNA therapeutics.
Impact: By directly countering inflammation that suppresses mRNA expression and worsens LNP immunogenicity, this work introduces a mechanistically rational strategy to enable effective mRNA therapeutics in inflammatory liver states.
Clinical Implications: If translated in vivo, this platform could improve efficacy of liver-targeted mRNA therapeutics during systemic inflammation, with potential relevance to sepsis-associated liver dysfunction.
Key Findings
- Inflammation globally suppresses mRNA expression and reduces hepatocyte uptake/translation of therapeutic mRNA; ionizable LNPs are immunogenic.
- A telodendrimer immune-modulating nanodrug inhibited endogenous and LPS-induced inflammation in liver cell systems.
- The nanodrug significantly enhanced mRNA/LNP delivery efficiency in liver cells, including primary human hepatocytes.
Methodological Strengths
- Cross-species evaluation including mouse and human immune cells and primary human hepatocytes.
- Mechanistic targeting of inflammation to enhance mRNA/LNP delivery demonstrated across multiple liver cell platforms.
Limitations
- Primarily in vitro/ex vivo work; in vivo efficacy, biodistribution, and safety are not reported.
- Sepsis-specific models and clinical translation remain to be established.
Future Directions: Test in animal models of inflammatory liver disease and sepsis, characterize pharmacokinetics/safety, and define synergy with therapeutic mRNA targets under clinically relevant inflammatory conditions.
Liver-specific delivery of mRNAs encoding key regulatory genes via lipid nanoparticles (LNPs) is promising to restore liver homeostasis and resume liver functions in inflammatory liver diseases. However, inflammation downregulates the global mRNA expression in general as a self-defensive mechanism, e.g., to block viral protein expression, which also reduces the efficiency of therapeutic mRNA delivered to hepatocytes. In addition, ionizable LNPs are immunogenic, which exacerbates inflammation. In this project, we applied a novel immune-modulating telodendrimer (TD) nanodrug (ND) to inhibit inflammation and improve specific mRNA delivery. We tested TD ND in both mouse and human immune cells, liver cell lines, and primary human hepatocytes (PHH) to inhibit endotoxin-induced inflammation. TD ND was able to inhibit both endogenous and LPS-induced inflammation in liver cells, which improved cell proliferation in culture and also significantly enhanced the efficiency of mRNA/LNP delivery both